FBRX — Forte Biosciences, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1419041 ·
Last close
$76.60
Market Cap
$1.57B
52W High
$77.20
52W Low
$15.51
ADV30
1,755,652
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -22,439,000 | -22,136,000 | 67,223,000 | 58,223,000 | 25,123,000 |
| Dec 2025 | 0 | — | -24,571,000 | -24,788,000 | 82,779,000 | 76,957,000 | 21,788,000 |
| Sep 2025 | 0 | — | -18,383,000 | -17,682,000 | 97,089,000 | 93,414,000 | 12,992,000 |
| Jun 2025 | 0 | — | -11,579,000 | -11,249,000 | 107,783,000 | 106,144,000 | 9,170,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-59,335,000
Investing CF
$-55,000
Financing CF
$71,757,000
CapEx
$-147,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-4.56
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-223,373,000
Inventory
—
Receivables
$817,000
ST Investments
$0
EBIT TTM
$-70,657,000
Pretax Income TTM
$-68,338,000
Interest Exp TTM
—
Analysts
4
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -70,657,000 | -69,375,000 | 82,779,000 | 21,788,000 | — | -50,882,000 |
| Dec 2024 | 0 | -36,602,000 | -35,478,000 | 61,561,000 | 9,081,000 | — | -30,745,000 |
| Dec 2023 | 0 | -32,486,000 | -31,476,000 | 38,980,000 | 3,666,000 | — | -28,706,000 |
| Dec 2022 | 0 | -13,896,000 | -13,879,000 | 41,997,000 | 3,179,000 | — | -8,185,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-4.04
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SRPT | Sarepta Therapeutics, Inc. | $1.57B | $14.86 | — |
| MLTX | MoonLake Immunotherapeutics | $1.57B | $18.44 | — |
| ANAB | ANAPTYSBIO, INC | $1.58B | $53.36 | — |
| SEPN | Septerna, Inc. | $1.55B | $34.45 | — |
| INVA | Innoviva, Inc. | $1.55B | $20.97 | — |
News headlines (Yahoo Finance, 1h cache)
The Charts Reveal Significant Price Movement in Forte Biosciences Stock Ahead of Argenx’s Acquisition Announcement
2026-07-30 14:15 · Yahoo
argenx Bets $2.2 Billion on a Vitiligo Breakthrough: What the Forte Biosciences Deal Means for Both Stocks
2026-07-29 07:45 · Yahoo
Forte Biosciences (FBRX) Agrees To argenx Takeover As Tender Offer Nears
2026-07-29 04:26 · Yahoo
argenx (ENXTBR:ARGX) Could Be 15% Above Fair Value On The Forte Deal
2026-07-28 10:09 · Yahoo
Argenx signs agreement to buy Forte Biosciences for $2.2bn
2026-07-28 09:35 · Yahoo
argenx (ENXTBR:ARGX) Stock Looks Fairly Valued With Modest Upside On Earnings
2026-07-28 09:11 · Yahoo
Why Did AAPL, FBRX, RTX Stocks Surge To 52-Week Highs Today?
2026-07-28 01:57 · Yahoo
The $2.2 Billion Reason Forte BioSciences (FBRX) Stock Is Skyrocketing Today
2026-07-27 20:28 · Yahoo
Update: US Equity Indexes Mixed as Tech Heads Lower, Crude Oil Sinks on Pause in Iran Strikes
2026-07-27 17:40 · Yahoo
Forte Biosciences shares surge after argenx agrees to acquire company for $2.2B
2026-07-27 16:23 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.